Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study

INTRODUCTION: Although liraglutide is widely recognized to have glycemic and extra-glycemic effects, few studies have compared these effects in relation to hypoglycemic treatment starting from the diagnosis of diabetes. We evaluated the effectiveness of liraglutide in reducing the Framingham risk sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciresi, Alessandro, Vigneri, Enrica, Radellini, Stefano, Pantò, Felicia, Giordano, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801224/
https://www.ncbi.nlm.nih.gov/pubmed/29139081
http://dx.doi.org/10.1007/s13300-017-0338-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801224/
https://www.ncbi.nlm.nih.gov/pubmed/29139081
http://dx.doi.org/10.1007/s13300-017-0338-4

Ejemplares similares